With dramatic changes in regulatory policies and a strong line on quality, China is outpacing the rest of Asia in attracting high quality contract research and contract manufacturing, writes Asia correspondent A Nair.
Outsourcing is no longer a tactical issue facing pharmaceutical companies. It is a strategic one. With China emerging central to many US pharmaceutical strategies, Chinese drug giants are enhancing their skills further to make a mark in the global market.
There is no doubt that outsourcing is booming in China, but what really makes China different from the rest of the outsourcing pack in Asia is its ability to attract high-end outsourcing work. China’s huge pharmaceutical market and its high future growth potential are attracting Big Pharma.
Research indicates that in 2012, the China pharma outsourcing market will continue to grow at an estimated rate of 22–26%, and is likely to reach the US$3.3bn mark by the end of the year.
With the availability of a large pool of talent, whose technical capability and skills are fast catching up, a growing number of Chinese drug companies are embarking on innovative drug r&d, primarily due to the support of the central and local governments and readily available funding opportunities from various sources.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.